Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.755 +0.335 (+23.59%)
Streaming Delayed Price Updated: 10:53 AM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,775,875
Open 1.400
Bid (Size) 1.750 (6)
Ask (Size) 1.760 (9)
Prev. Close 1.420
Today's Range 1.380 - 1.890
52wk Range 1.140 - 7.200
Shares Outstanding 58,576,350
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga

Performance

YTD
-66.4%
-66.4%
1 Month
-71.6%
-71.6%
3 Month
-66.4%
-66.4%
6 Month
-66.4%
-66.4%
1 Year
-57.7%
-57.7%

More News

Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. – ALDX
From Pomerantz LLP
Via GlobeNewswire
What's going on in today's session
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
11 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
ALDX BREAKING NEWS: BFA Law Announces an Investigation into Aldeyra Therapeutics, Inc. 75% Stock Drop; Investors are Notified to Contact BFA Law
From Bleichmar Fonti & Auld LLP
Via Business Wire
The market is filled with gapping stocks in Thursday's session.
Via Chartmill
Crude Oil Dips 7%; ISM Services PMI Falls In March
Via Benzinga
Exposures Fossil Fuels
Aldeyra Stock Slumps After FDA Says Investigational Drug For Dry Eyes Treatment Failed To Demonstrate Efficacy – Retail Stays Optimistic
Via Stocktwits
Topics Artificial Intelligence Bankruptcy
Exposures Artificial Intelligence Financial Legal
These stocks that are showing activity before the opening bell on Thursday.
Via Chartmill
Dow Tumbles Over 1,100 Points; US Initial Jobless Claims Fall
Via Benzinga
Topics Stocks
Exposures US Equities
FDA Rejects Aldeyra's Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%
Via Benzinga
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire

Frequently Asked Questions

Is Aldeyra Therapeutics, Inc. - Common Stock publicly traded?
Yes, Aldeyra Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Aldeyra Therapeutics, Inc. - Common Stock trade on?
Aldeyra Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock?
The ticker symbol for Aldeyra Therapeutics, Inc. - Common Stock is ALDX on the Nasdaq Stock Market
What is the current price of Aldeyra Therapeutics, Inc. - Common Stock?
The current price of Aldeyra Therapeutics, Inc. - Common Stock is 1.755
When was Aldeyra Therapeutics, Inc. - Common Stock last traded?
The last trade of Aldeyra Therapeutics, Inc. - Common Stock was at 04/04/25 10:53 AM ET
What is the market capitalization of Aldeyra Therapeutics, Inc. - Common Stock?
The market capitalization of Aldeyra Therapeutics, Inc. - Common Stock is 102.80M
How many shares of Aldeyra Therapeutics, Inc. - Common Stock are outstanding?
Aldeyra Therapeutics, Inc. - Common Stock has 103M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.